神冠控股(00829.HK)擬持續提升自動化生產水平
神冠控股(00829.HK)去年度收入受疫情影響,按年下跌3.6%至9.62億元人民幣(下同),財務總監吳旭陽指出,自動化生產與能源節約措施令銷售成本下降,加上政府補貼增加,帶動純利按年升20.3%,毛利率按年提升1.6個百分點至24.9%。
主席周亞仙表示,腸衣業務增長前景向好,對該業務審慎樂觀,預期今年總資本開支為1億元,當中主要用於繼續提升自動化及智能化生產,期望可節能及減少人手,抵消原料價格的波動,另有部分用於新產品投資及營銷。
吳旭陽補充,膠原蛋白食品、護膚品和醫用膠原蛋白三類新產品於去年均有明顯增長,共錄收入近4,000萬元,當中醫療用品及藥物產品佔約2,000萬至3,000萬元,雖然新產品佔收入比例不足一成,對未來業務佔比亦無明確目標,但預期在產品認受性逐步提高下,將可成為集團增長動力之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.